Atika Capital Management LLC Acquires Shares of 436,900 Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Atika Capital Management LLC has invested approximately $6.72 million in Teva Pharmaceutical Industries, acquiring 436,900 shares during the first quarter.
• Wall Street analysts have a positive outlook on Teva, with multiple firms upgrading ratings and setting price targets between $23.00 and $25.00.
• Teva's most recent earnings report showed a quarterly revenue of $4.18 billion, slightly below analyst expectations, with a reported EPS of $0.66.

Atika Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 436,900 shares of the company's stock, valued at approximately $6,715,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. increased its position in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after acquiring an additional 22,044,407 shares during the period. Duquesne Family Office LLC increased its position in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after acquiring an additional 7,569,450 shares during the period. Allspring Global Investments Holdings LLC increased its position in Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after acquiring an additional 5,186,592 shares during the period. Assenagon Asset Management S.A. increased its position in Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock valued at $91,973,000 after acquiring an additional 4,824,247 shares during the period. Finally, Nuveen LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $40,827,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 65,001 shares of company stock worth $996,958. 0.49% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on TEVA shares. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Finally, Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Down 1.8%

NYSE:TEVA traded down $0.3340 during trading hours on Friday, reaching $18.4660. The company had a trading volume of 13,290,711 shares, compared to its average volume of 13,180,406. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The firm has a market cap of $21.18 billion, a price-to-earnings ratio of -115.41, a P/E/G ratio of 1.09 and a beta of 0.62. The business's 50-day simple moving average is $16.75 and its two-hundred day simple moving average is $16.27. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's quarterly revenue was up .3% on a year-over-year basis. During the same period last year, the company posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.